Wellington Shields Capital Management LLC purchased a new stake in shares of PRA Health Sciences Inc (NASDAQ:PRAH) during the third quarter, HoldingsChannel reports. The fund purchased 5,000 shares of the medical research company’s stock, valued at approximately $551,000.

A number of other institutional investors have also added to or reduced their stakes in PRAH. BlackRock Inc. increased its position in PRA Health Sciences by 27.2% during the second quarter. BlackRock Inc. now owns 5,426,909 shares of the medical research company’s stock valued at $506,656,000 after acquiring an additional 1,159,446 shares during the last quarter. FMR LLC increased its position in PRA Health Sciences by 84.6% during the second quarter. FMR LLC now owns 2,295,675 shares of the medical research company’s stock valued at $214,324,000 after acquiring an additional 1,051,810 shares during the last quarter. Swedbank bought a new position in PRA Health Sciences during the third quarter valued at $104,802,000. Frontier Capital Management Co. LLC bought a new position in PRA Health Sciences during the third quarter valued at $78,126,000. Finally, Bank of New York Mellon Corp increased its position in PRA Health Sciences by 44.2% during the second quarter. Bank of New York Mellon Corp now owns 2,197,004 shares of the medical research company’s stock valued at $205,113,000 after acquiring an additional 673,202 shares during the last quarter. 98.82% of the stock is currently owned by institutional investors.

NASDAQ PRAH opened at $106.43 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.93 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $6.93 billion, a PE ratio of 28.54, a P/E/G ratio of 1.56 and a beta of 0.73. PRA Health Sciences Inc has a 12 month low of $76.39 and a 12 month high of $112.88.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, October 31st. The medical research company reported $1.13 EPS for the quarter, topping the Zacks’ consensus estimate of $1.07 by $0.06. The firm had revenue of $717.60 million for the quarter, compared to analysts’ expectations of $729.63 million. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The business’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 earnings per share. As a group, equities research analysts anticipate that PRA Health Sciences Inc will post 3.93 earnings per share for the current year.

A number of research firms have weighed in on PRAH. BidaskClub cut shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 8th. Barclays boosted their price objective on shares of PRA Health Sciences from $100.00 to $115.00 and gave the company an “overweight” rating in a research report on Thursday, August 2nd. SunTrust Banks boosted their price objective on shares of PRA Health Sciences to $120.00 and gave the company a “buy” rating in a research report on Monday, November 5th. Mizuho set a $100.00 price objective on shares of PRA Health Sciences and gave the company a “hold” rating in a research report on Monday, August 6th. Finally, Credit Suisse Group boosted their price objective on shares of PRA Health Sciences from $104.00 to $107.00 and gave the company an “outperform” rating in a research report on Thursday, August 2nd. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $111.50.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/11/10/wellington-shields-capital-management-llc-takes-551000-position-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.